(LYEL) Lyell Immunopharma - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US55083R1041

CAR-T, Dual-Target, Solid Tumor, Stem-Like T Cells

Biotechnology
Market Cap in USD: 532m
IPO / Inception: 2021-06-17
Return 12m vs S&P 500: 71.1%

EPS (Earnings per Share)

EPS (Earnings per Share) of LYEL over the last years for every Quarter: "2020-12": -3.1868, "2021-03": -0.84, "2021-06": -0.89, "2021-09": -0.2, "2021-12": -0.35, "2022-03": -0.28, "2022-06": -0.15, "2022-09": -0.28, "2022-12": -0.04, "2023-03": -0.23, "2023-06": -0.18, "2023-09": -0.17, "2023-12": -0.2, "2024-03": -0.2393, "2024-06": -0.18, "2024-09": -0.19, "2024-12": -0.445, "2025-03": -0.1784, "2025-06": -2.89, "2025-09": -2.13,
EPS CAGR: -27.14%
EPS Trend: -55.9%
Last SUE: 0.53
Qual. Beats: 0

Revenue

Revenue of LYEL over the last years for every Quarter: 2020-12: 2.312, 2021-03: 2.445, 2021-06: 2.628, 2021-09: 2.755, 2021-12: 2.822, 2022-03: 0.553, 2022-06: 35.741, 2022-09: 0.003, 2022-12: 48.386, 2023-03: 0.065, 2023-06: 0.027, 2023-09: 0.025, 2023-12: 0.013, 2024-03: 0.003, 2024-06: 0.013, 2024-09: 0.034, 2024-12: 0.011, 2025-03: 0.007, 2025-06: 0.008, 2025-09: 0.015,
Rev. CAGR: -75.26%
Rev. Trend: -63.9%
Last SUE: 0.02
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 90.1%
Value at Risk 5%th 134%
Relative Tail Risk -9.29%
Reward TTM
Sharpe Ratio 1.02
Alpha 62.46
CAGR/Max DD -0.31
Character TTM
Hurst Exponent 0.635
Beta 1.204
Beta Downside 1.500
Drawdowns 3y
Max DD 89.90%
Mean DD 57.66%
Median DD 59.40%

Description: LYEL Lyell Immunopharma December 03, 2025

Lyell Immunopharma (NASDAQ: LYEL) is a clinical-stage biotech focused on next-generation chimeric antigen receptor (CAR) T-cell therapies for hematologic cancers and solid tumors. Its platform combines genetic engineering tactics-c-Jun overexpression, NR4A3 knockout, Epi-R stem-like T-cell programming, CD62L-positive enrichment, and a synthetic-cell mimetic called Stim-R-to mitigate T-cell exhaustion and boost proliferation. The lead candidate, IMPT-314, is a dual-targeting CD19/CD20 CAR-T currently in a Phase 1/2 trial for relapsed/refractory large B-cell lymphoma, while its solid-tumor pipeline remains preclinical.

Key operating metrics (Q2 2024): cash and short-term investments of roughly $68 million, giving an estimated runway of 12-15 months at the current burn rate of $4-5 million per month. The CAR-T sector is projected to expand at a CAGR of ~15 % through 2030, driven by FDA approvals of all-ogeneic products and reimbursement reforms that favor outpatient administration. Lyell’s partnership pipeline-most notably a 2023 collaboration with Roche to explore its Stim-R platform-could provide non-dilutive funding and accelerate IND filings, though the timing and size of milestone payments remain uncertain.

For a deeper quantitative view of LYEL’s valuation and risk profile, the analytical dashboards on ValueRay can help you extend this initial assessment.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-325.7m TTM) > 0 and > 6% of Revenue (6% = 2460 TTM)
FCFTA -0.41 (>2.0%) and ΔFCFTA -15.35pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 722.7k% (prev 661.2k%; Δ 61.6kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.40 (>3.0%) and CFO -165.0m > Net Income -325.7m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 10.30 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (18.3m) change vs 12m ago 42.55% (target <= -2.0% for YES)
Gross Margin -19.8k% (prev -23.7k%; Δ 3876 pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 0.01% (prev 0.01%; Δ -0.00pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -1.69 (EBITDA TTM -190.4m / Interest Expense TTM 121.1m) >= 6 (WARN >= 3)

Altman Z'' -29.42

(A) 0.73 = (Total Current Assets 328.2m - Total Current Liabilities 31.9m) / Total Assets 408.0m
(B) -3.62 = Retained Earnings (Balance) -1.48b / Total Assets 408.0m
warn (B) unusual magnitude: -3.62 — check mapping/units
(C) -0.40 = EBIT TTM -204.6m / Avg Total Assets 513.6m
(D) -18.75 = Book Value of Equity -1.48b / Total Liabilities 78.8m
Total Rating: -29.42 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 22.27

1. Piotroski 0.0pt
2. FCF Yield -64.46%
3. FCF Margin data missing
4. Debt/Equity 0.13
5. Debt/Ebitda 0.42
6. ROIC - WACC (= -58.26)%
7. RoE -96.68%
8. Rev. Trend -63.90%
9. EPS Trend -55.95%

What is the price of LYEL shares?

As of January 12, 2026, the stock is trading at USD 24.55 with a total of 111,668 shares traded.
Over the past week, the price has changed by -12.35%, over one month by -26.52%, over three months by +45.87% and over the past year by +106.65%.

Is LYEL a buy, sell or hold?

Lyell Immunopharma has received a consensus analysts rating of 2.75. Therefor, it is recommend to hold LYEL.
  • Strong Buy: 0
  • Buy: 0
  • Hold: 3
  • Sell: 1
  • Strong Sell: 0

What are the forecasts/targets for the LYEL price?

Issuer Target Up/Down from current
Wallstreet Target Price 29.7 20.9%
Analysts Target Price 29.7 20.9%
ValueRay Target Price 24.1 -1.9%

LYEL Fundamental Data Overview January 09, 2026

P/S = 12979.537
P/B = 1.6169
Beta = -0.138
Revenue TTM = 41.0k USD
EBIT TTM = -204.6m USD
EBITDA TTM = -190.4m USD
Long Term Debt = 44.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 7.97m USD (from shortTermDebt, last fiscal year)
Debt = 44.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -79.3m USD (from netDebt column, last quarter)
Enterprise Value = 256.8m USD (532.2m + Debt 44.3m - CCE 319.6m)
Interest Coverage Ratio = -1.69 (Ebit TTM -204.6m / Interest Expense TTM 121.1m)
EV/FCF = -1.55x (Enterprise Value 256.8m / FCF TTM -165.5m)
FCF Yield = -64.46% (FCF TTM -165.5m / Enterprise Value 256.8m)
FCF Margin = -403.7k% (FCF TTM -165.5m / Revenue TTM 41.0k)
Net Margin = -794.3k% (Net Income TTM -325.7m / Revenue TTM 41.0k)
Gross Margin = -19.8k% ((Revenue TTM 41.0k - Cost of Revenue TTM 8.16m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev none%)
Tobins Q-Ratio = 0.63 (Enterprise Value 256.8m / Total Assets 408.0m)
Interest Expense / Debt = 11.89% (Interest Expense 5.26m / Debt 44.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -161.6m (EBIT -204.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.30 (Total Current Assets 328.2m / Total Current Liabilities 31.9m)
Debt / Equity = 0.13 (Debt 44.3m / totalStockholderEquity, last quarter 329.1m)
Debt / EBITDA = 0.42 (negative EBITDA) (Net Debt -79.3m / EBITDA -190.4m)
Debt / FCF = 0.48 (negative FCF - burning cash) (Net Debt -79.3m / FCF TTM -165.5m)
Total Stockholder Equity = 336.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -63.41% (Net Income -325.7m / Total Assets 408.0m)
RoE = -96.68% (Net Income TTM -325.7m / Total Stockholder Equity 336.8m)
RoCE = -53.68% (EBIT -204.6m / Capital Employed (Equity 336.8m + L.T.Debt 44.3m))
RoIC = -47.98% (negative operating profit) (NOPAT -161.6m / Invested Capital 336.8m)
WACC = 10.28% (E(532.2m)/V(576.4m) * Re(10.35%) + D(44.3m)/V(576.4m) * Rd(11.89%) * (1-Tc(0.21)))
Discount Rate = 10.35% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 20.15%
Fair Price DCF = unknown (Cash Flow -165.5m)
EPS Correlation: -55.95 | EPS CAGR: -27.14% | SUE: 0.53 | # QB: 0
Revenue Correlation: -63.90 | Revenue CAGR: -75.26% | SUE: 0.02 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-2.14 | Chg30d=+0.795 | Revisions Net=+2 | Analysts=2
EPS next Year (2026-12-31): EPS=-9.05 | Chg30d=+1.947 | Revisions Net=+4 | Growth EPS=+14.7% | Growth Revenue=-100.0%

Additional Sources for LYEL Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle